Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG for treating advanced/metastatic solid tumors in mainland China. This trial aims to evaluate the safety and efficacy of the combination therapy, which could offer more effective and safer clinical solutions, as no similar combination therapy has been approved globally.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company focused on developing innovative antibody-drug conjugates and monoclonal antibodies for the treatment of various cancers. The company is engaged in advancing clinical studies globally, with a market focus on solid tumors and lung cancer.
YTD Price Performance: 10.13%
Average Trading Volume: 1,671,714
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$14.54B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue